Literature DB >> 11122086

Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia.

M D Cappellini1, L Robbiolo, B M Bottasso, R Coppola, G Fiorelli, A P Mannucci.   

Abstract

Thromboembolic phenomena have been described in patients with thalassaemia intermedia and major, although there are relatively few epidemiological data on the overall frequency of these complications. To obtain more insight into the risk and mechanism of venous thromboembolism in thalassaemia, the aims of this study were: (i) to establish retrospectively the prevalence of thromboembolic events in a large group of adults with thalassaemia intermedia and major during a follow up period of 10 years; (ii) to measure in subgroups of these patients sensitive markers of activation of coagulation and fibrinolysis enzymes; and (iii) to look for possible procoagulant mechanisms. A high prevalence of thromboembolic events was found, particularly in splenectomized patients with thalassaemia intermedia (29%). These patients had high plasma levels of markers of coagulation and fibrinolysis activation. Furthermore, thalassaemic red cells and erythroid precursors from splenectomized patients with thalassaemia intermedia had an enhanced capacity to generate thrombin. To evaluate the role of splenectomy per se on procoagulant activity, we evaluated the capacity to form thrombin in healthy individuals who had been splenectomized for trauma. They produced the same amount of thrombin as non-splenectomized controls. In conclusion, the results of this study show the existence of a hypercoagulable state in splenectomized patients with thalassaemia intermedia and that their red and erythroid cells are capable of acting as activated platelets in thrombin generation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122086     DOI: 10.1046/j.1365-2141.2000.02376.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  68 in total

1.  Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia.

Authors:  A Phrommintikul; A Sukonthasarn; R Kanjanavanit; W Nawarawong
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 2.  Hypercoagulability in congenital haemolytic anaemias.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-10-25       Impact factor: 3.443

3.  Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?

Authors:  Giovanna Graziadei; Chiara Refaldi; Wilma Barcellini; Claudia Cesaretti; Elena Cassinero; Khaled M Musallam; Maria Domenica Cappellini
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

4.  Postsplenectomy thromboembolic disease in congenital sideroblastic anaemia.

Authors:  Michael T Byrne; Anke K Bergman; Angela I Ruiz; Bernard J Silver; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  BMJ Case Rep       Date:  2010-09-17

Review 5.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

6.  Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.

Authors:  Evangelia Yannaki; Thalia Papayannopoulou; Erica Jonlin; Fani Zervou; Garyfalia Karponi; Angeliki Xagorari; Pamela Becker; Nikoleta Psatha; Ioannis Batsis; Panayotis Kaloyannidis; Varvara Tahynopoulou; Varnavas Constantinou; Asimina Bouinta; Konstantia Kotta; Aglaia Athanassiadou; Achilles Anagnostopoulos; Athanasios Fassas; George Stamatoyannopoulos
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

7.  Hemolysis-associated pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Frans A Kuypers; Gregory J Kato; Lisa Lavrisha; Sandra Larkin; Titi Singer; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

8.  Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase.

Authors:  Emanuela Ferru; Antonella Pantaleo; Franco Carta; Franca Mannu; Amina Khadjavi; Valentina Gallo; Luisa Ronzoni; Giovanna Graziadei; Maria Domenica Cappellini; Francesco Turrini
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

9.  In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy.

Authors:  Vichai Atichartakarn; Pantep Angchaisuksiri; Katcharin Aryurachai; Suporn Chuncharunee; Ammarin Thakkinstian
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

10.  Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhood.

Authors:  Abhishek Maiti; Amartya Chakraborti; Puranjoy Chakraborty; Sanjay Mishra
Journal:  Australas Med J       Date:  2012-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.